Last updated: February 24, 2026
What is the Scope of the Methylating Agent Drug Class?
Methylating agents are compounds that transfer methyl groups to nucleophilic sites on DNA, proteins, and small molecules. They are primarily used in cancer chemotherapy and as research tools. The class includes both alkylating agents with non-specific DNA reactivity and targeted methylating agents designed for selectivity.
Key Drugs in the Class
- Temozolomide (TMZ): Approved for glioblastoma multiforme and melanoma.
- Dacarbazine: Used in melanoma, Hodgkin's lymphoma.
- Decitabine & Azacitidine: DNA methyltransferase inhibitors, classified as hypomethylating agents.
Market Size and Growth
The global methylating agent market was valued at approximately USD 1.5 billion in 2022. Projected CAGR from 2023 to 2030 is around 8%.
| Region |
Market Size (USD Billion, 2022) |
Growth Rate (CAGR, 2023-2030) |
| North America |
0.65 |
7.5% |
| Europe |
0.40 |
8% |
| Asia-Pacific |
0.30 |
9% |
| Rest of World |
0.15 |
8.5% |
Drivers:
- Increasing prevalence of cancers such as gliomas, melanomas, and hematologic malignancies.
- Development of targeted methylating agents with improved safety profiles.
- Expanding approval and off-label use of existing agents.
Challenges:
- Toxicity and side effects associated with non-specific alkylating agents.
- Resistance mechanisms developing in tumor cells.
- Competition from other epigenetic and targeted therapies.
Key Market Players
| Company |
Major Drugs |
Market Position |
R&D Focus |
| Merck & Co. |
Temozolomide |
Market leader |
New formulations, combination therapies |
| Bristol-Myers Squibb |
Dacarbazine |
Established |
Novel derivatives |
| Novartis |
Decitabine, Azacitidine |
Leader in epigenetic drugs |
Targeted methylation modulation |
| AstraZeneca |
Emerging methylating agents |
Investing in targeted agents |
Overcoming resistance |
Patent Landscape Overview
Patent Filing Trends (2010–2022)
- Steady increase in patent applications worldwide, peaking around 2018.
- Major jurisdictions: US, Europe, China.
- Focus areas: Novel methylating or alkylating compounds, targeted delivery systems, combination therapies.
Patent Types and Content
- Compound Patents: Cover new chemical structures with methylating activity, e.g., derivatives of temozolomide.
- Formulation Patents: Extended release, nanoparticle encapsulation, targeted delivery.
- Method-of-Use Patents: New indications or combination use cases.
- Biological Patents: Biomarkers predicting response, methylation status.
Notable Patent Filings by Major Players
| Year |
Company |
Patent Focus |
Status |
| 2018 |
Merck |
Temozolomide derivatives |
Granted/Family extending to 2030 |
| 2019 |
Novartis |
Targeted methylation delivery |
Pending/Grant |
| 2020 |
BMS |
Combination therapies with Dacarbazine |
Granted |
Patent Expiry and Freedom-to-Operate
- Key patents for Temozolomide expire around 2027–2028 in the US and Europe.
- Patents for Dacarbazine filing from the early 1980s extend into the early 2030s.
- Increasing presence of generic formulations post-expiry, impacting market share pricing.
Competitive Landscape Shaping
- Patent expiries will open markets for generic or biosimilar methylating agents.
- Continuous innovation in targeted delivery aims to extend patent life.
- Licensing and collaborations are prevalent, especially in Asia, to access newer compounds and formulations.
Regulatory Environment Impact
- US FDA approvals for new indications extend patent life via method claims.
- EMA and other agencies streamline approval for targeted methylating agents, influencing patent strategies.
- Orphan drug designation for specific methylating agents boosts exclusivity periods.
Summary of Strategic Opportunities
- Developing combination therapies pairing methylating agents with immune checkpoint inhibitors.
- Focus on personalized medicine via biomarkers predicting response.
- Innovating delivery systems to mitigate toxicity and resistance.
Key Takeaways
- The methylating agent market is growing driven by cancer therapy needs and new formulations.
- Patent activity peaked around 2018 with a shift towards targeted delivery patents.
- Major patents for first-generation agents expire soon, creating opportunities for generics.
- Continuous innovation and strategic patenting extend market exclusivity.
- Regulatory pathways support new uses and formulations, influencing patent tactics.
FAQs
Q1. When do most patents on temozolomide expire?
Patents for temozolomide in the US and Europe are set to expire around 2027–2028, opening the market for generics.
Q2. Which regions have the most patent filings for methylating agents?
The US, Europe, and China lead in patent filings, reflecting their market size and innovation activity.
Q3. What are the main challenges in the methylating agent market?
Toxicity, resistance, and the emergence of safer, more targeted agents pose significant challenges.
Q4. How are companies extending patent protection?
Through new derivatives, targeted delivery systems, combination therapies, and method-of-use claims.
Q5. What prospects exist for generic methylating agents?
Post-patent expiry, generics will likely capture significant market share, pressuring brand pricing strategies.
References
[1] Market Research Future. (2023). Global Methylating Agents Market Report.
[2] GlobalData. (2022). Cancer Treatment and Therapeutics Trends.
[3] U.S. Patent and Trademark Office. (2023). Patent Filings Archive.
[4] European Patent Office. (2022). Patent Trends in Oncology Drugs.
[5] PubMed. (2023). Advances in Targeted Delivery of Methylating Agents.
